Patents Examined by Janet L. Anders
  • Anti-inflammatory polypeptides
    Patent number: 9845358
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic
  • Tropomyosin-related kinase inhibitors
    Patent number: 9328096
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
    Patent number: 8877741
    Abstract: The invention relates to new pyrrolidine derivatives of the formula to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Fleck, Niklas Heine, Bernd Nosse, Gerald Juergen Roth
  • Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
    Patent number: 8697876
    Abstract: The present invention provides a novel polymorph of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide (Form A) characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure. This polymorph is useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine. The invention also provides a process for the synthesis of pyridinoylpiperidine compounds of Formula I in high yield and high purity. In particular, the provides a process for the preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide, its hemisuccinate salt and polymorph (Form A).
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: April 15, 2014
    Assignee: Colucid Pharmaceuticals, Inc.
    Inventors: Jean-Francois Carniaux, Jonathan Cummins
  • Condensed pyridine derivatives useful as potent inhibitors of the protein kinase CK2
    Patent number: 8686144
    Abstract: The invention relates to the use of specific compounds of formula (I) and their pharmaceutically-acceptable salts: (Formula 1) (I) as a new family of protein kinase CK2 inhibitors; the invention also relates to the use of compounds of formula (I) for the preparation of pharmaceutical compositions for the prevention and/or treatment of disorders and/or diseases chosen amongst cancers; autoimmune and inflammatory diseases; infectious diseases; diabetes angiogenesis related disorders; retinopathies and cardiac hypertrophy.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: April 1, 2014
    Assignees: Commissariat a l'Energie Atomique et aux Energie Alternative, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Claude Cochet, Renaud Prudent, Virginie Moucadel, Chi-Hung N'guyen
  • Cytotoxic agents containing novel potent taxanes and their therapeutic use
    Patent number: 7414073
    Abstract: Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a link, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: August 19, 2008
    Assignee: Immunogen Inc.
    Inventors: Erkan Baloglu, Michael Miller, Ravi V. J. Chari